NY-JEFFERIES-FINANCIAL
28.5.2020 18:04:07 CEST | Business Wire | Press release
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease.
Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000.
“We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charities globally as this is truly a tragedy that affects all of us and, in particular, those who are most disadvantaged and in the greatest need.
The charities selected are both big and small and represent everything from food banks, child care services, assistance with PPE and other medical supplies, support for front line medical workers, assistance for afflicted military personnel, local teen centers, support for police and fire, workforce training and re-training and many other worthy areas that are most in need. We thank our employees and clients for aiding in the selection of many of these remarkable charities.
Finally, all of us at Jefferies would like to thank all the dedicated professionals working tirelessly on the front line to help those in need. They are the true heroes whom we are honored to help in Peg’s name.”
Contributions in the following amounts will be immediately distributed to these respected organizations:
NYC Mayor’s Fund | Peg’s Cure |
|
$ 150,000 |
All Hands and Hearts |
|
$ 150,000 |
American Heart Association |
$ 150,000 |
|
Bowery Mission |
$ 150,000 |
|
Hackensack Meridian Health Foundation |
$ 150,000 |
|
Houston Police Foundation |
|
$ 150,000 |
International Rescue Committee |
|
$ 150,000 |
Robin Hood Foundation |
|
$ 150,000 |
Strive |
|
$ 150,000 |
The Bass Foundation |
|
$ 150,000 |
World Central Kitchen |
|
$ 150,000 |
We Can #TogetherFromHome |
|
$ 100,000 |
Achievement First |
|
$ 100,000 |
Aktion Deutschland Hilft |
|
$ 100,000 |
Alzheimer’s Association |
|
$ 100,000 |
Ambitious About Autism |
|
$ 100,000 |
Barnardo’s |
$ 100,000 |
|
BMS Family Health and Wellness Center |
|
$ 100,000 |
Bob Woodruff Foundation |
|
$ 100,000 |
Boys & Girls Clubs of the Austin Area |
|
$ 100,000 |
Brewers Community Foundation |
|
$ 100,000 |
Buttle UK |
|
$ 100,000 |
Central Texas Food Bank |
|
$ 100,000 |
Chelsea and Westminster Hospital NHS Foundation Trust |
|
$ 100,000 |
Chrysalis |
$ 100,000 |
|
City Harvest |
$ 100,000 |
|
Citymeals on Wheels |
|
$ 100,000 |
Columbia Children's Hospital |
|
$ 100,000 |
Community Food Bank of New Jersey |
|
$ 100,000 |
Covenant House |
|
$ 100,000 |
Doctors Without Borders |
|
$ 100,000 |
East High – EOP (Education Partnership Organization) |
|
$ 100,000 |
Elmhurst Hospital Charity |
|
$ 100,000 |
Family Promise of Bergen County |
|
$ 100,000 |
FarmLink |
|
$ 100,000 |
Feeding America |
|
$ 100,000 |
Food Bank For New York City |
|
$ 100,000 |
Foodlink |
|
$ 100,000 |
Habitat for Humanity Japan |
|
$ 100,000 |
Hance Family Foundation |
|
$ 100,000 |
Humanity & Inclusion |
|
$ 100,000 |
Hunger Free America |
|
$ 100,000 |
Imperial Health Charity |
|
$ 100,000 |
Kids in Crisis |
|
$ 100,000 |
Kohka Foundation |
|
$ 100,000 |
Lahey Clinic Foundation |
|
$ 100,000 |
Mail Force Charity |
|
$ 100,000 |
Martha’s Table |
|
$ 100,000 |
Médecins Sans Frontières |
|
$ 100,000 |
Memorial Hermann Foundation |
|
$ 100,000 |
My Sister's Place |
|
$ 100,000 |
National Emergencies Trust |
|
$ 100,000 |
Navajo Nation Covid-19 Relief Fund |
|
$ 100,000 |
Nazareth Housing |
|
$ 100,000 |
Neighbourly Community Fund |
|
$ 100,000 |
NHS Charities Together |
|
$ 100,000 |
Northwell Health's COVID-19 Emergency Fund |
|
$ 100,000 |
NYU Langone |
|
$ 100,000 |
Off Their Plate |
|
$ 100,000 |
Oxfam India |
|
$ 100,000 |
Philippine Disaster Resilience Foundation |
|
$ 100,000 |
Red Hook Initiative |
|
$ 100,000 |
Rosetree Trust |
|
$ 100,000 |
Royal College of Nursing Foundation |
|
$ 100,000 |
RVNAhealth |
|
$ 100,000 |
Second Harvest |
|
$ 100,000 |
Sempre Con Voi (Always with You) |
|
$ 100,000 |
St Michael’s House |
|
$ 100,000 |
TBD 1 |
|
$ 100,000 |
TBD 2 |
|
$ 100,000 |
TBD 3 |
|
$ 100,000 |
TCF Bank |
|
$ 100,000 |
The Care Workers Charity |
|
$ 100,000 |
The River Fund New York |
|
$ 100,000 |
The United Way of Central Indiana COVID-19 Relief Fund |
|
$ 100,000 |
The World Health Organization (WHO) |
|
$ 100,000 |
Trinity's Services & Food for the Homeless |
|
$ 100,000 |
The Trussell Trust |
|
$ 100,000 |
UNICEF |
|
$ 100,000 |
UR Medicine Home Care’s Meals on Wheels |
|
$ 100,000 |
URMC COVID-19 Emergency Fund |
|
$ 100,000 |
Valpo Surf Project, Inc. |
|
$ 100,000 |
Volunteers of Legal Service |
|
$ 100,000 |
Our Dream Their Smile |
|
$ 100,000 |
West Side Campaign Against Hunger |
|
$ 100,000 |
Women United in Philanthropy |
|
$ 100,000 |
Women's Center of Greater Danbury |
|
$ 100,000 |
|
|
|
Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005663/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
